Who are Rhofade Cream, 1%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oxymetazoline HCL Cream 1.0%, CarVeDilol-SR (Slow Release), norepinephrine+vasopressin, Xylometazoline 0,1%, Norepinephrine intra-arteriel/hepatic, Placebo to Prazosin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rhofade-cream-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rhofade Cream, 1% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rhofade Cream, 1% (Rhofade Cream, 1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic agonist. Area: Dermatology.

phase 3 Alpha-1 adrenergic agonist Alpha-1 adrenergic receptor Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Rhofade Cream, 1% (Rhofade Cream, 1%) — Actavis Inc.. Oxymetazoline is an alpha-1 adrenergic agonist that constricts blood vessels in the skin to reduce facial redness and flushing.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Rhofade Cream, 1% TARGET	Rhofade Cream, 1%	Actavis Inc.	phase 3	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
Oxymetazoline HCL Cream 1.0%	Oxymetazoline HCL Cream 1.0%	Allergan	marketed	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
CarVeDilol-SR (Slow Release)	CarVeDilol-SR (Slow Release)	Seoul National University Bundang Hospital	marketed	Beta-blocker with alpha-1 blocking activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
norepinephrine+vasopressin	norepinephrine+vasopressin	Peking Union Medical College Hospital	marketed	Vasopressor combination	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, vasopressin V1 receptor
Xylometazoline 0,1%	Xylometazoline 0,1%	Rigshospitalet, Denmark	marketed	Alpha-1 adrenergic agonist (nasal decongestant)	Alpha-1 adrenergic receptor
Norepinephrine intra-arteriel/hepatic	Norepinephrine intra-arteriel/hepatic	University Health Network, Toronto	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor
Placebo to Prazosin	Placebo to Prazosin	Brian J Lipworth	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic agonist class)

Allergan · 2 drugs in this class
EMS · 1 drug in this class
Institute of Liver and Biliary Sciences, India · 1 drug in this class
Medical University of Graz · 1 drug in this class
Rawalpindi Medical College · 1 drug in this class
Tehran Heart Center · 1 drug in this class
Actavis Inc. · 1 drug in this class
University Tunis El Manar · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rhofade Cream, 1% — Competitive Intelligence Brief. https://druglandscape.com/ci/rhofade-cream-1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing